Maria Jose Serrano
Overview
Explore the profile of Maria Jose Serrano including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
46
Citations
684
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Denninghoff V, Garrido-Navas M, Molina-Vallejo M, Garcia-Diaz A, Perez-Villares J, Colmenero-Ruiz M, et al.
J Liq Biopsy
. 2025 Mar;
2:100005.
PMID: 40028486
Liquid biopsy (LB) is a minimally invasive procedure that detects biomarkers in body fluids for real-time monitoring of patients. This study developed a new LB approach to analyze Circulating Epithelial...
2.
Fusco N, Jantus-Lewintre E, Serrano M, Gandara D, Malapelle U, Rolfo C
Crit Rev Oncol Hematol
. 2025 Jan;
104619.
PMID: 39824370
Liquid biopsy (LB) has revolutionized molecular pathology, offering non-invasive insights into tumor biology. However, widespread adoption is hindered by a lack of standardized protocols, requiring robust quality control and harmonized...
3.
Garcia-Diaz A, Moyano-Rodriguez M, Garrido-Navas M, de Miguel-Perez D, Exposito-Hernandez J, Alcazar-Navarrete B, et al.
Arch Bronconeumol
. 2024 Oct;
61(3):156-165.
PMID: 39414465
Introduction: Non-small cell lung cancer (NSCLC) is the most common type of lung neoplasm. Despite surgical resection, it has a high relapse rate, accounting for 30-55% of all cases. Next-generation...
4.
Reduzzi C, Nicolo E, Singhal S, Venetis K, Ortega-Franco A, de Miguel-Perez D, et al.
Crit Rev Oncol Hematol
. 2024 Aug;
203:104483.
PMID: 39159706
Circulating tumor cells (CTCs) enumeration and molecular profiling hold promise in revolutionizing the management of solid tumors. Their understanding has evolved significantly over the past two decades, encompassing pivotal biological...
5.
Gonzalez A, Diaz C, Mena C, Valenzuela C, Cooper A, Inostroza P, et al.
Rev Med Chil
. 2024 Aug;
151(8):1078-1087.
PMID: 39093200
Background: The Public Health Services at the Metropolitan Region (MR) of Chile have nine acute psychiatric beds per 100,000 inhabitants, under international recommendations. Aim: The present study will evaluate the...
6.
7.
de Miguel-Perez D, Ortega F, Tejada R, Martinez-Unica A, Peterson C, Russo A, et al.
Biomark Res
. 2023 Nov;
11(1):98.
PMID: 37968730
Concurrent chemoradiotherapy (cCRT) is the mainstay of treatment for patients diagnosed with locally advanced non-small cell lung cancer (NSCLC). One significant challenge in the effectiveness of this therapy is the...
8.
Serrano M, Rolfo C, Exposito-Hernandez J, Garrido-Navas C, Lopez-Hidalgo J, Denninghoff V
Int Rev Cell Mol Biol
. 2023 Sep;
381:113-129.
PMID: 37739481
Cancer interception (CI) is a new approach to cancer prevention and treatment in a cancer-risk population that aims to detect and treat pre-tumoral stages. It has several potential advantages over...
9.
Gonzalez-Martinez C, Garrido-Navas C, Alcaide-Lucena M, Lorente J, Lopez-Hidalgo J, Ortega F, et al.
Crit Rev Oncol Hematol
. 2023 Jun;
188:104060.
PMID: 37353177
miRNAs have been widely identified as important players in cancer development and progression. Metastasis in breast cancer can occur as relapse of a treated primary tumour or at the time...
10.
Calero-Castro F, Pereira S, Laga I, Villanueva P, Suarez-Artacho G, Cepeda-Franco C, et al.
Int J Mol Sci
. 2023 Mar;
24(5).
PMID: 36901704
Circulating Tumor Cells (CTCs) are considered a prognostic marker in pancreatic cancer. In this study we present a new approach for counting CTCs and CTC clusters in patients with pancreatic...